Publications

by | May 4, 2012 | Uncategorized

EMA reflection paper discusses globalisation of clinical trials

The European Medicines Agency (EMA) has published the final reflection paper on ethical and good clinical practice aspects of clinical trials of medicinal products for human use. Conducted outside of the EU/EEA and submitted in marketing authorisation, it produced several applications to the EU regulatory authorities.

Entering into force on 1 May 2012, the EMA reflection paper aims to strengthen existing processes to provide assurance to regulators and stakeholders that clinical trials meet the required ethical and Good Clinical Practice standards (GCP), no matter where in the world they have been conducted.

It is part of the Agency’s strategy developed to address the challenges arising from the increasing globalisation of clinical trials implying different regulatory frameworks and research cultures. Yet regulators, healthcare professionals and patients all rely on the same clinical trial data when making decisions on whether or not to allow a medicine on the market or use a medicine.

EPHA related articles

– [->5074]
– [->5063]
– [->5014]
– [->5000]
– [->4967]
– [->4782]
– [->4764]
– [->4062]

Get the EPHA Newsletter

The best of our activities, right in your inbox!